BIO vs. NVO: Bio-Rad Laboratories vs. Novo Nordisk Stock Comparison

Company Profile

Bio-Rad Laboratories (BIO) and Novo Nordisk (NVO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while NVO is classified in Pharmaceuticals.

Bio-Rad Laboratories (BIO) trades as ordinary local shares, while Novo Nordisk (NVO) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Novo Nordisk (NVO) is heavily traded at around 12.11M shares per day, whereas Bio-Rad Laboratories (BIO) sees a more moderate 250.78K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Bio-Rad Laboratories (BIO) at 14.27% and Novo Nordisk (NVO) at 58.38% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Bio-Rad Laboratories (BIO) at 39.45% and Novo Nordisk (NVO) at 33.92% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Novo Nordisk (NVO) at 40.05% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.

Profitability Metrics

Growth

Both Bio-Rad Laboratories (BIO) at 0.65% and Novo Nordisk (NVO) at 6.43% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Novo Nordisk (NVO) reports EPS growth of 1.77%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Novo Nordisk (NVO) at 0.85 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NVO.

Both Bio-Rad Laboratories (BIO) at 0.18 and Novo Nordisk (NVO) at 0.62 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Bio-Rad Laboratories (BIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a yield of 29.03%, ranking against industry peers normally.

Bio-Rad Laboratories (BIO) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Novo Nordisk (NVO) reports a payout of 45.36%, ranking against industry peers normally.

Dividend Metrics

Valuation

Both Bio-Rad Laboratories (BIO) at 10.14 and Novo Nordisk (NVO) at 10.18 sit in the cheaper earnings-multiple quartile for P/E ratio, with the market paying less for a dollar of trailing earnings than it pays for typical peers.

Novo Nordisk (NVO) at 0.53 sits in the cheaper P/S ratio quartile while Bio-Rad Laboratories (BIO) at 3.96 prices around its industry’s middle — NVO costs less per dollar of sales, though read it alongside growth and margins.

Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile against book while Novo Nordisk (NVO) at 5.43 is valued near its industry’s middle — BIO is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics